Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced cancer: KQB198 trial launches

NCT ID NCT06507306

Disease control Sponsor: Kumquat Biosciences Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 03, 2026 · Updated 4 times

Summary

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have not responded to other treatments. The study aims to find a safe dose and see if KQB198 can shrink tumors when used alone or with other cancer drugs. About 100 participants will take the drug daily and have regular clinic visits for monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

92 people

The number who actually took part.

Started

Jun 2024

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * PART 1 - Histologically confirmed diagnosis of a solid tumor malignancy with any of the following oncogenic mutations: EGFR, RAS, PTPN11, or SOS1 mutations, or inactivating mutations of NF1. * PART 1 - (Osimertinib and Amivantamab arms) and Part 2 Cohort A and Cohort B: Histologically confirmed diagnosis of NSCLC with activating EGFR mutation and progression on osimertinib * Part 3 - Cohort A: Histologically confirmed diagnosis of NSCLC with exon 20 insertion EGFR mutation * Unresectable or metastatic disease * No available treatment with curative intent * Adequate organ function * Measurable disease per RECIST 1.1. Exclusion Criteria: * Prior therapy with a similar mechanism of action to KQB198 * History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow * History of interstitial lung disease * Cardiac abnormalities

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced solid tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Solid tumor, adult

Contacts and locations

Locations

  • CHU Bordeaux - Hopital Saint-Andre

    Bordeaux, Nouvelle-Aquitane, 33000, France

  • CHU de Nantes - Hopital Nord Laennec

    Nantes, Pays de la Loire Region, 44000, France

  • Clinica Universidad de Navarra - Pamplona

    Pamplona, 31008, Spain

  • David H. Koch Center for Cancer Center at Memorial Sloan Kettering Cancer Center

    Long Island City, New York, 11101, United States

  • Florida Cancer Specialists - Sarasota

    Sarasota, Florida, 34232, United States

  • Fondazione Policlinico Universitario A. Gemelli IRCCS - Universita Cattolica del Sacro Cuore

    Rome, Lazio, 00168, Italy

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Hospital Quirónsalud Málaga

    Málaga, 29004, Spain

  • Hospital Universitari Quiron Dexeus Barcelona

    Barcelona, Catalonia, 08028, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario Vall d'Hebron

    Barcelona, Catalonia, 08035, Spain

  • IUCT-Oncopole

    Toulouse, Occitaine, 31059, France

  • Institut Paoli-Calmettes

    Marseille, Bouches-du-Rhône, 13009, France

  • Institut de Cancerologie de l'Ouest - site St-Herblain

    Saint-Herblain, Loire-Atlantique, 44800, France

  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

    Naples, 80131, Italy

  • New Experimental Therapeutics (NEXT) Oncology Barcelona

    Barcelona, 08023, Spain

  • New Experimental Therapeutics (NEXT) Oncology Madrid - Hospital Quironsalud Madrid

    Madrid, 28223, Spain

  • New Experimental Therapeutics of San Antonio - NEXT Oncology

    San Antonio, Texas, 78229, United States

  • New Experimental Therapeutics of Virginia - NEXT Oncology

    Fairfax, Virginia, 22031, United States

  • Sarah Cannon Research Institute at Florida Cancer Specialists - Lake Nona -

    Orlando, Florida, 32827, United States

  • Sarah Cannon Research Institute at HealthONE

    Denver, Colorado, 80218, United States

  • Sarah Cannon and HCA Research Institute

    Nashville, Tennessee, 37203, United States

  • South Texas Accelerated Research Therapeutics (START) Barcelona- HM Nou Delfos

    Barcelona, 08023, Spain

  • South Texas Accelerated Research Therapeutics (START) Madrid - CIOCC

    Madrid, 28040, Spain

  • South Texas Accelerated Research Therapeutics (START) Madrid - Hospital Fundacion Jimenez Diaz

    Madrid, Spain

  • The Lindner Center for Research and Education at The Christ Hospital

    Cincinnati, Ohio, 45219, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.